Lung Cancer | Specialty

Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer

September 1st 2020

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Updates on I/O Therapy for Non-Driver mNSCLC

September 1st 2020

EGFR Exon 20 Mutations in NSCLC

September 1st 2020

KRAS-Mutant NSCLC

September 1st 2020

HER2 Targeted Therapy for Treatment of NSCLC

September 1st 2020

MET Exon 14 Mutations in mNSCLC

September 1st 2020

RET Fusion+ mNSCLC

September 1st 2020

Dr. Horn on the Role of Mobocertinib in NSCLC

August 28th 2020

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Dr. Pennell on the Evolution of Targeted Treatment in NSCLC

August 27th 2020

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer

August 27th 2020

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Dr. Duma on the Importance of Mitigating Racial Disparities in Lung Cancer Research

August 26th 2020

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research. 

First-Line Extensive-Stage Small Cell Lung Cancer: Examining the New Role of Combination Chemotherapy and Immunotherapy

August 26th 2020

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC

August 25th 2020

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLC

August 25th 2020

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

FDA Approves Generic Pemetrexed for Nonsquamous NSCLC

August 25th 2020

The FDA has approved a generic form of pemetrexed for intravenous administration as a single-agent in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that has not progressed following 4 cycles of first-line platinum-based chemotherapy.

Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer

August 25th 2020

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

August 25th 2020

The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.

Dr. Sabari on Novel Immunotherapy Combos Under Investigation in NSCLC

August 24th 2020

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Expert Perspectives on the Identification and Management of Drug-Induced Interstitial Lung Disease

August 24th 2020

Experts share insight on their clinical experience with interstitial lung disease.

Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers

August 22nd 2020

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.